Watch AVHHL. Know when insiders buy.
One email the day a filing lands. Free.
AVHHL
AVITA Medical, Inc.
2.00
+0.00 +0.00%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
75
PASS · shorts 75
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $61.9MP/E —DIV YIELD —FCF YIELD -39.80%REV TTM $75.6M +1.0%NET INCOME −$43.1MNET DEBT $37.5M52W 0.56 – 2.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $21.7M | +17.8% | 81.9% | −$6.9M | −$7.7M | — | -0.25 | −$3.5M | $108K | −$3.6M | Aug 6 |
| Q1 2026 · Mar 31 | $19.3M | +4.0% | 81.7% | −$8.8M | −$10.6M | — | -0.35 | −$10.1M | $19K | −$10.1M | May 14 |
| Q4 2025 · Dec 31derived | $17.6M | −4.3% | 81.2% | −$10.4M | −$11.6M | — | -0.37 | −$5.4M | −$674K | −$4.8M | Aug 6 |
| Q3 2025 · Sep 30 | $17.1M | −12.7% | 81.3% | −$9.2M | −$13.2M | — | -0.46 | −$5.2M | $934K | −$6.2M | Nov 6 |
| Q2 2025 · Jun 30 | $18.4M | +21.2% | 81.2% | −$11.1M | −$9.9M | — | -0.38 | −$10.2M | $524K | −$10.8M | Aug 6 |
| Q1 2025 · Mar 31 | $18.5M | +66.7% | 84.7% | −$11.8M | −$13.9M | — | -0.53 | −$10.3M | $221K | −$10.5M | May 14 |
| Q4 2024 · Dec 31derived | $18.4M | +29.7% | 87.6% | −$10M | −$11.6M | — | -0.44 | −$8M | $1.6M | −$9.7M | Aug 6 |
| Q3 2024 · Sep 30 | $19.5M | +43.2% | 83.7% | −$13.8M | −$16.2M | — | -0.62 | −$7.2M | $3.8M | −$11M | Nov 6 |
| Q2 2024 · Jun 30 | $15.2M | — | 86.1% | −$15.6M | −$15.4M | — | -0.60 | −$12.8M | $2.7M | −$15.4M | Aug 8 |
| Q1 2024 · Mar 31 | $11.1M | — | 86.4% | −$17.2M | −$18.7M | — | -0.73 | −$20.9M | $1.1M | −$22M | May 8 |
| Q4 2023 · Dec 31derived | $14.2M | — | 87.3% | −$12.3M | −$7.1M | — | -0.28 | −$10.9M | $296K | −$11.2M | Feb 13 |
| Q3 2023 · Sep 30 | $13.6M | — | 84.5% | −$9.3M | −$8.7M | — | -0.34 | −$9M | $502K | −$9.5M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $71.6M | 82.1% | −$42.5M | −$48.6M | -67.8% | -1.74 | −$31.2M | $1M | −$32.2M | — | — |
| FY2024 · to Dec 31 | $64.3M | 85.8% | −$56.6M | −$61.8M | -96.3% | -2.39 | −$48.9M | $9.2M | −$58.1M | — | — |
| FY2023 · to Dec 31 | $50.1M | 84.5% | −$42.7M | −$35.4M | -70.6% | -1.40 | −$38M | $1.4M | −$39.4M | — | — |
| FY2022 · to Dec 31 | $34.4M | 82.4% | −$27.5M | −$26.7M | -77.5% | 1.07 | −$19.1M | $452K | −$19.5M | — | — |
| FY2021 · to Jun 30 | $29.2M | 79.6% | −$26.5M | −$26.6M | -90.9% | 1.17 | −$25.9M | $894K | −$26.8M | — | — |
| FY2020 · to Jun 30 | $14.3M | 79.2% | −$42.7M | −$42M | -294.7% | 2.07 | −$22.7M | $590K | −$23.3M | — | — |
Every number comes from AVITA Medical, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.